Ambu falls after Danske Bank downgrades on urology concerns
Ambu shares plunged 9.4% to 56.75 DKK after Danske Bank downgraded the stock to “sell” and slashed its price target to 58 DKK, citing faster-than-expected competition and price pressure in urology, weak ureteroscope traction, and a limited product portfolio versus rivals, despite ongoing share buybacks and recent endoscopy growth.